> Beta cyclodextrin as a cholesterol reducing agent

Beta cyclodextrin as a cholesterol reducing agent


Beta cyclodextrin as a cholesterol reducing agent

Cardiovascular disease from atherosclerosis is one of the most common causes of death worldwide. Inflammation plays a crucial role in atherosclerosis and cholesterol crystals are considered to be early triggers in the development of the disease.

An international team has now found that cyclodextrin dissolves cholesterol crystals and reduces atherosclerotic plaques. This is a promising therapeutic approach for treating atherosclerosis. Their find was published in Science Translational Medicine.

Cyclodextrin works by reprogramming macrophages so that they do not cause such a strong inflammatory response in blood vessels that contain cholesterol crystals. The cyclodextrin also dissolves cholesterol crystals so that the cholesterol can be excreted from the body in urine. The result is prevention of plaque formation and even atherosclerotic plaque reduction in mice. Furthermore, when researchers used cyclodextrin to treat biopsies of plaques from human carotid arteries, they found similar results.

The study points to cholesterol crystals as a target for treatment of atherosclerosis, meaning that using cyclodextrin to dissolve the crystals could affect how the disease is treated.

The original idea for the test of cyclodextrin came from Chris Hempel, an American mother whose twin daughters are affected by a rare illness called Niemann-Pick Type C disease, in which cholesterol accumulates in the body. The children are being treated with cyclodextrin with promising results.

Hempel read about previous research on cholesterol crystals conducted by senior researcher Eicke Latz from the University Hospital Bonn and his colleagues from the Center of Molecular Inflammation Research (CEMIR) at the Norwegian University of Science and Technology (NTNU) in Trondheim. She contacted Dr. Latz to suggest that they test cyclodextrin as a possible treatment for atherosclerosis.

Methods: Underdog Pharmaceuticals has developed a novel class of cyclodextrin (CD) molecules for the encapsulation of toxic oxidized cholesterol. Oxidized cholesterol accumulates over time and causes dysfunction in many cell types, linking it to several age-related diseases including atherosclerosis. Presently, treatments for atherosclerosis are invasive, expensive, and/or show limited benefits. CDs are cyclic glucose oligomers, utilized to capture small, hydrophobic molecules. Here, a combination of in silico, in vitro, and ex vivo methods are used to implement a synergistic rational drug design strategy for developing CDs to remove atherogenic oxidized cholesterol from cells and tissues.

Results: UDP-003 can both prevent and reverse the formation of foam cells in-vitro and shrink plaques in ApoE-/- HF diet mice. UDP-003 binds and clears 7KC from in-vivo and ex-vivo systems selectivity, and it has an excellent safety profile. UDP-003 has been awarded the Innovative Licensing and Access Pathway (ILAP) Innovation Passport by the UK MHRA, which is accelerating Underdog’s path to clinic and will facilitate rapid and innovative clinical trials.

cyclodextrin plaque removal

Conclusions: Targeted removal of 7KC from plaque with proprietary cyclodextrin compounds has the potential to prevent and reverse the formation of atheroscloertic plaques. This innovation represents the first disease-modifying therapeutic approach to treating atherosclerosis.

My personal experience is that has reduced my plaque

 Read more




Previous Post Next Post